Working with U.S. Department of Defense, Canopus BioPharma, Inc. Announces Phase II Human Clinical Trial for Innovative Hepatitis C Drug, CB5300
LOS ANGELES--(BUSINESS WIRE)--Canopus BioPharma, Inc. (OTC:CBIA);(www.canopusbiopharma.com) today announced that permission has been granted by the U.S. Department of Defense to initiate a Hepatitis C efficacy and safety human clinical Phase II trial, testing the patented antiviral drug CB5300.